Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

KLHL20 and its role in cell homeostasis: A new perspective and therapeutic potential

The Functions and Properties of Cullin-5, a Potential Therapeutic Target for Cancers.

Cullin-RING ligases in regulation of autophagy

Targeting kelch-like (KLHL) proteins: Achievements, challenges and perspectives

Ubiquitin-specific Protease 20 in Human Disease: Emerging Role and Therapeutic Implications

A review: targeting UBR5 domains to mediate emerging roles and mechanisms - chance or necessity?

The role of ubiquitination in health and disease

Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing Pathways in Neurodegenerative Disorders and Cancer

Kelch-like Proteins: Physiological Functions and Relationships with Diseases

The Emerging Role of Ubiquitin-Specific Protease 20 in Tumorigenesis and Cancer Therapeutics

Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Role of UCHL3 in Health and Disease

Ste20-like kinase SLK, at the crossroads: a matter of life and death

Diverse Roles of the E2/E3 Hybrid Enzyme UBE2O in the Regulation of Protein Ubiquitination, Cellular Functions, and Disease Onset

E3 ligase recruitment by UBQLN2 protects substrates from proteasomal degradation

The role of ubiquitination in tumorigenesis and targeted drug discovery

Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options

Cullin-RING Ligases as attractive anti-cancer targets.

Emerging Roles of Non-proteolytic Ubiquitination in Tumorigenesis